How it works, simply
It blocks the IL-23 receptor, interrupting a specific inflammatory signal.
What the evidence tells us
The FDA snapshot describes four randomized trials supporting the original product approval.
Its psoriasis evidence does not establish treatment of every inflammatory condition, and it is not an injectable vial product.
Approved use: United States: Icotyde for moderate-to-severe plaque psoriasis in adults and patients aged 12 or older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.
Watch with PEP 7
A short introduction; the sources and limitations remain important.
Open video guide
Video guides are coming soon.
Risks and open questions
This brief guide does not summarize every contraindication or interaction. Use the current label for the exact product; the label directory is linked below.
Research and education only. PepGuide does not recommend medicines, doses or protocols.
Technical details and study context
Mechanism: Blocks the IL-23 receptor pathway involved in inflammatory signaling.
Sponsor or developer: Janssen Biotech
Studied or labeled topics: Plaque psoriasis
2026-03-17: FDA approval of oral Icotyde for specified plaque psoriasis populations.
Commercial blend names and research vials do not inherit a medicine’s approval or manufacturing controls.
Sources and review dates
- FDA: Icotyde trial snapshot ↗ · Regulator · 2026-03-17
Readability updated October 10, 2026. Evidence review: September 23, 2026 (listed facts only). A wording update is not a new clinical review.